CY1118104T1 - Νεα κυτταροστατικα νουκλεοζιδια 7-αποαζαπουρινης - Google Patents

Νεα κυτταροστατικα νουκλεοζιδια 7-αποαζαπουρινης

Info

Publication number
CY1118104T1
CY1118104T1 CY20161101041T CY161101041T CY1118104T1 CY 1118104 T1 CY1118104 T1 CY 1118104T1 CY 20161101041 T CY20161101041 T CY 20161101041T CY 161101041 T CY161101041 T CY 161101041T CY 1118104 T1 CY1118104 T1 CY 1118104T1
Authority
CY
Cyprus
Prior art keywords
apoazapurini
new
nuclear cells
compounds
nuclear
Prior art date
Application number
CY20161101041T
Other languages
Greek (el)
English (en)
Inventor
Michal Hocek
Petr Naus
Original Assignee
Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic filed Critical Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic
Publication of CY1118104T1 publication Critical patent/CY1118104T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14Pyrrolo-pyrimidine radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • HELECTRICITY
    • H02GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
    • H02JELECTRIC POWER NETWORKS; CIRCUIT ARRANGEMENTS OR SYSTEMS FOR SUPPLYING OR DISTRIBUTING ELECTRIC POWER; SYSTEMS FOR STORING ELECTRIC ENERGY
    • H02J7/00Circuit arrangements for charging or discharging batteries or for supplying loads from batteries
    • H02J7/40Circuit arrangements for charging or discharging batteries or for supplying loads from batteries characterised by the exchange of charge or discharge related data
    • H02J7/44Circuit arrangements for charging or discharging batteries or for supplying loads from batteries characterised by the exchange of charge or discharge related data between battery management systems and power sources
    • HELECTRICITY
    • H02GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
    • H02JELECTRIC POWER NETWORKS; CIRCUIT ARRANGEMENTS OR SYSTEMS FOR SUPPLYING OR DISTRIBUTING ELECTRIC POWER; SYSTEMS FOR STORING ELECTRIC ENERGY
    • H02J7/00Circuit arrangements for charging or discharging batteries or for supplying loads from batteries
    • H02J7/485Circuit arrangements for charging or discharging batteries or for supplying loads from batteries with provisions for charging different types of batteries

Landscapes

  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Power Engineering (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
CY20161101041T 2008-01-18 2016-10-19 Νεα κυτταροστατικα νουκλεοζιδια 7-αποαζαπουρινης CY1118104T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2224708P 2008-01-18 2008-01-18
PCT/CZ2009/000004 WO2009089804A1 (en) 2008-01-18 2009-01-15 Novel cytostatic 7-deazapurine nucleosides

Publications (1)

Publication Number Publication Date
CY1118104T1 true CY1118104T1 (el) 2017-06-28

Family

ID=40434932

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20161101041T CY1118104T1 (el) 2008-01-18 2016-10-19 Νεα κυτταροστατικα νουκλεοζιδια 7-αποαζαπουρινης
CY20181101120T CY1121364T1 (el) 2008-01-18 2018-10-30 Νεοι κυτταροστατικοι νουκλεοζιτες 7-δεαζαπουρινης

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20181101120T CY1121364T1 (el) 2008-01-18 2018-10-30 Νεοι κυτταροστατικοι νουκλεοζιτες 7-δεαζαπουρινης

Country Status (18)

Country Link
US (1) US8093226B2 (enExample)
EP (2) EP2231689B1 (enExample)
JP (2) JP5485172B2 (enExample)
CN (1) CN101977923B (enExample)
AU (1) AU2009204568B2 (enExample)
CA (1) CA2711384C (enExample)
CY (2) CY1118104T1 (enExample)
DK (2) DK3133080T3 (enExample)
ES (2) ES2598503T3 (enExample)
HR (2) HRP20161344T1 (enExample)
HU (2) HUE041598T2 (enExample)
LT (2) LT2231689T (enExample)
NZ (1) NZ586610A (enExample)
PL (2) PL2231689T3 (enExample)
PT (2) PT2231689T (enExample)
SI (2) SI3133080T1 (enExample)
TR (1) TR201815961T4 (enExample)
WO (1) WO2009089804A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103214484B (zh) 2005-12-13 2016-07-06 因塞特控股公司 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶
HUE029236T2 (en) 2007-06-13 2017-02-28 Incyte Holdings Corp (R) -3- (4- (7H-Pyrrolo [2,3-d] pyrimidin-4-yl) -1H-pyrazol-1-yl) -3-cyclopentylpropanenitrile Crystalline salts of Janus kinase inhibitor
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
PT2421879E (pt) * 2009-04-22 2013-12-09 Acad Of Science Czech Republic Novos 7-deazapurina nucleósidos para utilizações terapêuticas
MY156727A (en) * 2009-05-22 2016-03-15 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EP2432472B1 (en) 2009-05-22 2019-10-02 Incyte Holdings Corporation 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EP3354652B1 (en) 2010-03-10 2020-05-06 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
AR084691A1 (es) 2010-05-21 2013-06-05 Incyte Corp Formulacion de uso topico para un inhibidor de jak y metodo para tratar trastorno de la piel
KR101817221B1 (ko) * 2010-11-18 2018-01-10 카시나 라일라 이노바 파마슈티칼스 프라이빗 리미티드 치환된 4-(셀레노펜-2(또는 3)-일아미노)피리미딘 화합물 및 이의 사용방법
WO2012068440A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
CA2818542A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
MY165963A (en) 2011-06-20 2018-05-18 Incyte Holdings Corp Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為jak抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲jak抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
TWI761825B (zh) 2012-11-15 2022-04-21 美商英塞特控股公司 盧梭利替尼之緩釋性劑型
MX384910B (es) 2013-03-06 2025-03-14 Incyte Holdings Corp Procesos e intermedios para hacer un inhibidor de jak.
SG11201600815WA (en) 2013-08-07 2016-03-30 Incyte Corp Sustained release dosage forms for a jak1 inhibitor
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
JP6650074B2 (ja) 2016-06-29 2020-02-19 ウスタフ オルガニッケ ヘミエ アー ビオヘミエ アカデミエ ヴェド ツェーエル,ヴェー.ヴェー.イー 治療に使用するための、置換チエノピロロピリミジンリボヌクレオシド
CZ307334B6 (cs) 2016-08-02 2018-06-13 Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v.v.i. Substituované heteropentadieno-pyrrolopyrimidinové ribonukleosidy pro terapeutické použití
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
JP7393348B2 (ja) 2018-01-30 2023-12-06 インサイト・コーポレイション (1-(3-フルオロ-2(トリフルオロメチル)イソニコチニル)ピぺリジン―4-オン)を作製するためのプロセス及び中間体
CZ308104B6 (cs) 2018-03-12 2020-01-08 Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v. v. i. Pyridinopyrrolopyrimidinové ribonukleosidy pro terapeutické použití
CN113768934A (zh) 2018-03-30 2021-12-10 因赛特公司 使用jak抑制剂治疗化脓性汗腺炎
WO2020206289A1 (en) * 2019-04-05 2020-10-08 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5
BR112021025443A2 (pt) * 2019-06-18 2022-02-01 Taiho Pharmaceutical Co Ltd Compostos de éster fosfato com esqueleto de pirrolopirimidina ou sal farmaceuticamente aceitável do mesmo, agentes antitumorais e composições farmacêuticas compreendendo os ditos compostos, bem como usos e usos terapêuticos dos mesmos
WO2021164848A1 (en) * 2020-02-17 2021-08-26 Katholieke Universiteit Leuven Novel 6-substituted 7-deazapurines and corresponding nucleosides as medicaments
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CN112190590A (zh) * 2020-11-06 2021-01-08 牡丹江医学院 一种治疗动脉粥样硬化的硒核苷及其药物组合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS50125033A (enExample) * 1974-03-19 1975-10-01
IL108523A0 (en) 1993-02-03 1994-05-30 Gensia Inc Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain
JPH10158293A (ja) * 1996-08-08 1998-06-16 Rikagaku Kenkyusho 3’−デオキシリボヌクレオチド誘導体
JP3318579B2 (ja) * 1997-07-07 2002-08-26 理化学研究所 Dnaの塩基配列決定方法
JP3489991B2 (ja) * 1997-07-07 2004-01-26 理化学研究所 3’−デオキシリボヌクレオチド誘導体
CZ9901996A3 (cs) 1999-06-04 2001-01-17 Ústav organické chemie a biochemie AV ČR Nové 6-fenylpurinové 9-ß-D-ribonukleosidy s antineoplastickým účinkem, jejich použití k přípravě farmaceutických preparátů a farmaceutické přípravky, které je obsahují
AU2002353165A1 (en) * 2001-12-17 2003-06-30 Ribapharm Inc. Deazapurine nucleoside libraries and compounds
KR20060123707A (ko) 2003-08-27 2006-12-04 바이오타, 인코포레이티드 치료제로서의 신규 트리시클릭 뉴클레오시드 또는뉴클레오티드
AU2005317081A1 (en) * 2004-10-21 2006-06-22 Merck & Co., Inc. Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of RNA-dependent RNA viral infection
CN101043893A (zh) * 2004-10-21 2007-09-26 默克公司 治疗RNA-依赖性RNA病毒感染的氟化吡咯并[2,3-d]嘧啶核苷
TW200720285A (en) * 2005-04-25 2007-06-01 Genelabs Tech Inc Nucleoside compounds for treating viral infections

Also Published As

Publication number Publication date
EP3133080B1 (en) 2018-08-01
NZ586610A (en) 2012-08-31
CA2711384C (en) 2016-07-26
CN101977923B (zh) 2014-10-08
HUE030767T2 (en) 2017-05-29
EP2231689B1 (en) 2016-07-20
US20090203637A1 (en) 2009-08-13
JP5485172B2 (ja) 2014-05-07
AU2009204568B2 (en) 2013-10-03
CA2711384A1 (en) 2009-07-23
EP2231689A1 (en) 2010-09-29
SI3133080T1 (sl) 2018-12-31
JP2014058567A (ja) 2014-04-03
EP3133080A1 (en) 2017-02-22
ES2598503T3 (es) 2017-01-27
US8093226B2 (en) 2012-01-10
DK2231689T3 (en) 2016-09-19
LT3133080T (lt) 2018-11-12
DK3133080T3 (en) 2018-11-26
HRP20181774T1 (hr) 2018-12-28
TR201815961T4 (tr) 2018-11-21
CY1121364T1 (el) 2020-05-29
JP2011509949A (ja) 2011-03-31
PT2231689T (pt) 2016-10-07
HUE041598T2 (hu) 2019-05-28
CN101977923A (zh) 2011-02-16
AU2009204568A1 (en) 2009-07-23
HRP20161344T1 (hr) 2016-11-18
ES2693551T3 (es) 2018-12-12
LT2231689T (lt) 2016-10-25
PL2231689T3 (pl) 2017-01-31
PT3133080T (pt) 2018-11-16
WO2009089804A1 (en) 2009-07-23
PL3133080T3 (pl) 2018-12-31
SI2231689T1 (sl) 2016-11-30

Similar Documents

Publication Publication Date Title
CY1121364T1 (el) Νεοι κυτταροστατικοι νουκλεοζιτες 7-δεαζαπουρινης
CY1125550T1 (el) Ορισμενες τριαζολοπυραζινες, συνθεσεις αυτων και μεθοδοι για τη χρηση αυτων
UY36907A (es) Nuevas carboxamidas de acción microbiocida
CY1119534T1 (el) Παραγωγα φωσφορου ως αναστολεις κινασης
CY1118129T1 (el) 5-αλκυνυλ-πυριμιδινες
CR20140135A (es) Nuevos derivados de aril-quinolina
CY1118680T1 (el) Φαρμακευτικη συνθεση
CY1118187T1 (el) Χημικες ενωσεις
ECSP10010722A (es) Compuestos orgánicos
DOP2014000033A (es) Aminoquinazolinas como inhibidores de quinasa
EA201170832A1 (ru) Пуриновые соединения
EA201001205A1 (ru) Соединения, содержащие циклобутоксигруппу
CY1114793T1 (el) Παραγωγα αμινοπυραζολιου
EA201070519A1 (ru) Соединения тропана
MX2013004004A (es) Pirrolidinonas como inhibidores de metionina aminopeptidasa (metap-2).
PH12013500942A1 (en) Triazolopyridine compounds
PA8855001A1 (es) Monocarbamas
JO2673B1 (en) New diosmetin compounds, a process for their preparation and pharmaceutical compositions containing them
UA106880C2 (uk) Нові гербіциди
ECSP11011245A (es) Novedosos herbicidas
CY1118593T1 (el) Πρωτοτυπα παραγωγα πυραζινης
EA201101097A1 (ru) Новые микробиоциды
CY1120133T1 (el) Πυριδαζινονες ως αναστολεις ενζυμου daao
UY29486A1 (es) Compuestos utiles en terapia
EA201001855A1 (ru) Соединения, содержащие циклобутоксигруппу